Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poseltinib - Hanmi Pharmaceutical

Next Previous
Drug Profile

Poseltinib - Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641; NB-02 - NOBO Medicine

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly and Company; Hanmi Pharmaceutical; NOBO Medicine
  • Class Antineoplastics; Antirheumatics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Lymphoma
  • Phase I Marginal zone B-cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 08 Dec 2025 Seoul National University Hospital plans a phase I/II Go-Pro-DLBCL trial for Diffuse-large-B-cell-lymphoma (Combination-therapy, Second-line or greater therapy) in South Korea (PO) in January 2026 (NCT07269639)
  • 17 Nov 2025 Phase-I clinical trials in Marginal zone B-cell lymphoma (Combination therapy, Second-line therapy or greater) (unspecified route) (NOBO Medicine pipeline, November 2025)
  • 17 Nov 2025 NOBO Medicine initiates a phase I trial for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) at an unknown location (NOBO Medicine pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top